Picture of United Therapeutics logo

UTHR United Therapeutics Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapSuper Stock

Momentum

Relative Strength (%)
1m+3.13%
3m-14.3%
6m-10.98%
1yr-25.38%
Volume Change (%)
10d/3m+46.53%
Price vs... (%)
52w High-11.33%
50d MA+5.43%
200d MA+2.44%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)9.65
PEG Ratio (f)0.67
EPS Growth (f)16.9%
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value1.82
Price to Tang. Book1.86
Price to Free Cashflow14.6
Price to Sales4.69
EV to EBITDA6.96

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital18.62%
Return on Equity18.27%
Operating Margin50.91%

Financial Summary

Year End 31st DecUnit201920202021202220232024E2025ECAGR / Avg
Total Revenue$m1,448.81,483.31,685.51,936.32,327.52,715.992,849.437.41%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%+14.72-28.43+9.26+18.55+30.73+20.43+2.59n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of United Therapeutics EPS forecast chart

Profile Summary

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
June 26th, 1996
Public Since
June 17th, 1999
No. of Shareholders
31
No. of Employees
1,168
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
47,058,545

UTHR Share Price Performance

Upcoming Events for UTHR

United Therapeutics Corp at TD Cowen Health Care Conference

Q1 2024 United Therapeutics Corp Earnings Release

United Therapeutics Corp Annual Shareholders Meeting

Q2 2024 United Therapeutics Corp Earnings Release

Similar to UTHR

Picture of 2Seventy Bio logo

2Seventy Bio

us flag iconNASDAQ Global Select Market

Picture of 4D Molecular Therapeutics logo

4D Molecular Therapeutics

us flag iconNASDAQ Global Select Market

Picture of AbCellera Biologics logo

AbCellera Biologics

us flag iconNASDAQ Global Select Market

Picture of AbSci logo

AbSci

us flag iconNASDAQ Global Select Market

Picture of Acadia Pharmaceuticals logo

Acadia Pharmaceuticals

us flag iconNASDAQ Global Select Market

FAQ